Clinical Pharmacokinetics

Single-Isomer Drugs: True Therapeutic Advances
pp. 279-285(7)
Author: Andersson T.

Single-Enantiomer Drugs: Elegant Science, Disappointing Effects
pp. 287-290(4)
Authors: Mansfield P.; Henry D.; Tonkin A.

Pharmacokinetic Enhancement of Protease Inhibitor Therapy
pp. 291-310(20)
Authors: King J.R.; Wynn H.; Brundage R.; Acosta E.P.

Clinical Pharmacokinetics of Thalidomide
pp. 311-327(17)
Authors: Teo S.K.; Colburn W.A.; Tracewell W.G.; Kook K.A.; Stirling D.I.; Jaworsky M.S.; Scheffler M.A.; Thomas S.D.; Laskin O.L.

Pharmacokinetics and Subjective Effects of Sublingual Buprenorphine, Alone or in Combination with Naloxone: Lack of Dose Proportionality
pp. 329-340(12)
Authors: Harris D.S.; Mendelson J.E.; Lin E.T.; Upton R.A.; Jones R.T.

Lack of Effect of Omeprazole or of an Aluminium Hydroxide/Magnesium Hydroxide Antacid on the Pharmacokinetics of Lumiracoxib
pp. 341-348(8)
Authors: Scott G.; Christine Vinluan Reynolds; Milosavljev S.; Langholff W.; Shenouda M.; Rordorf C.